Business Description
Legend Biotech Corp
NAICS : 541714
SIC : 2834
ISIN : US52490G1022
Share Class Description:
LEGN: ADRDescription
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.98 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -0.67 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 7.09 | |||||
| Beneish M-Score | -0.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 36.6 | |||||
| 3-Year EBITDA Growth Rate | -2.5 | |||||
| 3-Year EPS without NRI Growth Rate | -2.8 | |||||
| 3-Year FCF Growth Rate | -3.3 | |||||
| 3-Year Book Growth Rate | 15.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 157.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.23 | |||||
| 9-Day RSI | 24.68 | |||||
| 14-Day RSI | 26.34 | |||||
| 6-1 Month Momentum % | -13.02 | |||||
| 12-1 Month Momentum % | -17.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.92 | |||||
| Quick Ratio | 6.83 | |||||
| Cash Ratio | 6.05 | |||||
| Days Inventory | 38.05 | |||||
| Days Sales Outstanding | 29.51 | |||||
| Days Payable | 60.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 | |||||
| Shareholder Yield % | -1.45 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.42 | |||||
| Operating Margin % | -154.13 | |||||
| Net Margin % | -181.75 | |||||
| FCF Margin % | -137.92 | |||||
| ROE % | -48.03 | |||||
| ROA % | -31.76 | |||||
| ROIC % | -127.91 | |||||
| ROC (Joel Greenblatt) % | -271.03 | |||||
| ROCE % | -35.44 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 27.84 | |||||
| PB Ratio | 6.58 | |||||
| Price-to-Tangible-Book | 7.51 | |||||
| EV-to-EBIT | -14.25 | |||||
| EV-to-Forward-EBIT | -14.64 | |||||
| EV-to-EBITDA | -14.56 | |||||
| EV-to-Forward-EBITDA | -14.94 | |||||
| EV-to-Revenue | 24.9 | |||||
| EV-to-Forward-Revenue | 10.72 | |||||
| EV-to-FCF | -18.05 | |||||
| Price-to-Net-Current-Asset-Value | 9.15 | |||||
| Price-to-Net-Cash | 11.59 | |||||
| Earnings Yield (Greenblatt) % | -7.02 | |||||
| FCF Yield % | -4.77 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers